{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:48:29Z","timestamp":1760647709042},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Headache Impact Test (HIT-6) and the Chronic Headache Questionnaire (CH-QLQ) measure headache-related quality of life but are not preference-based and therefore cannot be used to generate health utilities for cost-effectiveness analyses. There are currently no established algorithms for mapping between the HIT-6 or CH-QLQ and preference-based health-related quality-of-life measures for chronic headache population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We developed algorithms for generating EQ-5D-5L and SF-6D utilities from the HIT-6 and the CHQLQ using both direct and response mapping approaches. A multi-stage model selection process was used to assess the predictive accuracy of the models. The estimated mapping algorithms were derived to generate UK tariffs and was validated using the Chronic Headache Education and Self-management Study (CHESS) trial dataset.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Several models were developed that reasonably accurately predict health utilities in this context. The best performing model for predicting EQ-5D-5L utility scores from the HIT-6 scores was a Censored Least Absolute Deviations (CLAD) (1) model that only included the HIT-6 score as the covariate (mean squared error (MSE) 0.0550). The selected model for CH-QLQ to EQ-5D-5L was the CLAD (3) model that included CH-QLQ summary scores, age, and gender, squared terms and interaction terms as covariates (MSE 0.0583). The best performing model for predicting SF-6D utility scores from the HIT-6 scores was the CLAD (2) model that included the HIT-6 score and age and gender as covariates (MSE 0.0102). The selected model for CH-QLQ to SF-6D was the OLS (2) model that included CH-QLQ summary scores, age, and gender as covariates (MSE 0.0086).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The developed algorithms enable the estimation of EQ-5D-5L and SF-6D utilities from two headache-specific questionnaires where preference-based health-related quality of life data are missing. However, further work is needed to help define the best approach to measuring health utilities in headache studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12874-022-01762-y","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:03:50Z","timestamp":1666767830000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mapping between headache specific and generic preference-based health-related quality of life measures"],"prefix":"10.1186","volume":"22","author":[{"given":"Kamran","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hema","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjit","family":"Matharu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Norman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Achana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"issue":"8","key":"1762_CR1","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, et al. A six-item short-form survey for measuring headache impact: the HIT-6\u2122. Qual Life Res. 2003;12(8):963\u201374.","journal-title":"Qual Life Res"},{"issue":"10","key":"1762_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/03331024211006045","volume":"41","author":"KL Haywood","year":"2021","unstructured":"Haywood KL, et al. Measuring health-related quality of life in chronic headache: A comparative evaluation of the Chronic Headache Quality of Life Questionnaire and Headache Impact Test (HIT-6). Cephalalgia. 2021;41(10):100\u20131123.","journal-title":"Cephalalgia."},{"issue":"3","key":"1762_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1526-4610.2011.01997.x","volume":"52","author":"CL Bagley","year":"2012","unstructured":"Bagley CL, et al. Validating migraine\u2010specific quality of life questionnaire v2. 1 in episodic and chronic migraine. Headache. 2012;52(3):409\u201321.","journal-title":"Headache"},{"key":"1762_CR4","volume-title":"NICE process and methods guides, in guide to the methods of technology appraisal 2013","author":"National Institute for H and E Care","year":"2013","unstructured":"National Institute for H and E Care. NICE process and methods guides, in guide to the methods of technology appraisal 2013. London: National Institute for Health and Care Excellence (NICE); 2013."},{"key":"1762_CR5","volume-title":"NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values","author":"L Longworth","year":"2011","unstructured":"Longworth L, Rowen D. NICE DSU technical support document 10: the use of mapping methods to estimate health state utility values. 2011."},{"issue":"3","key":"1762_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"Group TE","year":"1990","unstructured":"Group TE. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"issue":"10","key":"1762_CR7","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"key":"1762_CR8","unstructured":"Ware J, et al. How to score: version 2 of the SF-12v2 Health Survey. Boston, MA: Health Assessment Lab.\u00a02002;22(32.9):32\u201335."},{"issue":"9","key":"1762_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","volume":"42","author":"JE Brazier","year":"2004","unstructured":"Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851\u20139.","journal-title":"Med Care"},{"key":"1762_CR10","doi-asserted-by":"publisher","unstructured":"Patel S, et al. Usual care and a self-management support programme versus usual care and a relaxation programme for people living with chronic headache disorders: a randomised controlled trial protocol (CHESS). BMJ Open. 2020;10(4):e033520. https:\/\/doi.org\/10.1136\/bmjopen-2019-033520.","DOI":"10.1136\/bmjopen-2019-033520"},{"issue":"4","key":"1762_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","volume":"38","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, et al. Development and validation of the migraine-specific quality of life questionnaire. Headache. 1998;38(4):295\u2013302.","journal-title":"Headache"},{"issue":"10","key":"1762_CR12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/03331024211006045","volume":"41","author":"KL Haywood","year":"2021","unstructured":"Haywood KL, et al. Measuring health-related quality of life in chronic headache: a comparative evaluation of the chronic headache quality of life questionnaire and Headache Impact Test (HIT-6). Cephalalgia. 2021;41(10):1100\u201323.","journal-title":"Cephalalgia"},{"issue":"2","key":"1762_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","volume":"21","author":"J Brazier","year":"2002","unstructured":"Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271\u201392.","journal-title":"J Health Econ"},{"issue":"7133","key":"1762_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/bmj.316.7133.736","volume":"316","author":"P Kind","year":"1998","unstructured":"Kind P, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316(7133):736\u201341.","journal-title":"BMJ"},{"key":"1762_CR15","volume-title":"Guide to the methods of technology appraisal","author":"NICE U","year":"2013","unstructured":"NICE U. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence (NICE); 2013."},{"issue":"1","key":"1762_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-6-73","volume":"6","author":"AR Levy","year":"2008","unstructured":"Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes. 2008;6(1):1\u20138.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"1762_CR17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/(SICI)1099-1255(199611)11:6<619::AID-JAE418>3.0.CO;2-1","volume":"11","author":"LE Papke","year":"1996","unstructured":"Papke LE, Wooldridge JM. Econometric methods for fractional response variables with an application to 401 (k) plan participation rates. J Appl Economet. 1996;11(6):619\u201332.","journal-title":"J Appl Economet"},{"issue":"4","key":"1762_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1257\/jep.15.4.29","volume":"15","author":"KY Chay","year":"2001","unstructured":"Chay KY, Powell JL. Semiparametric censored regression models. J Econ Perspect. 2001;15(4):29\u201342.","journal-title":"J Econ Perspect"},{"issue":"3","key":"1762_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0304-4076(84)90004-6","volume":"25","author":"JL Powell","year":"1984","unstructured":"Powell JL. Least absolute deviations estimation for the censored regression model. J Econom. 1984;25(3):303\u201325.","journal-title":"J Econom"},{"key":"1762_CR20","doi-asserted-by":"crossref","unstructured":"McCullagh P, Nelder, JA.\u00a0Generalized linear models. Routledge; 2019.","DOI":"10.1201\/9780203753736"},{"issue":"1","key":"1762_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/0272989X05284108","volume":"26","author":"AM Gray","year":"2006","unstructured":"Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making. 2006;26(1):18\u201329.","journal-title":"Med Decis Making"},{"issue":"1","key":"1762_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2018","unstructured":"Devlin NJ, et al. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2018;27(1):7\u201322.","journal-title":"Health Econ"},{"key":"1762_CR23","volume-title":"Stata Statistical Software: Release 15","author":"StataCorp","year":"2017","unstructured":"StataCorp. Stata Statistical Software: Release 15. College Station: StataCorp LLC.; 2017."},{"issue":"6","key":"1762_CR24","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jval.2014.07.001","volume":"17","author":"KA Khan","year":"2014","unstructured":"Khan KA, et al. Mapping between the Roland Morris Questionnaire and generic preference-based measures. Value in Health. 2014;17(6):686\u201395.","journal-title":"Value in Health"},{"key":"1762_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-4612-1694-0_15","volume-title":"Selected papers of hirotugu akaike","author":"H Akaike","year":"1998","unstructured":"Akaike H. Information theory and an extension of the maximum likelihood principle. In: Selected papers of hirotugu akaike. Springer; 1998. p. 199\u2013213."},{"issue":"2","key":"1762_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10198-011-0364-5","volume":"14","author":"B Kaambwa","year":"2013","unstructured":"Kaambwa B, Billingham L, Bryan S. Mapping utility scores from the Barthel index. Eur J Health Econ. 2013;14(2):231\u201341.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1762_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11136-009-9558-z","volume":"19","author":"H Dakin","year":"2010","unstructured":"Dakin H, et al. Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire. Qual Life Res. 2010;19(1):65\u201380.","journal-title":"Qual Life Res"},{"issue":"6","key":"1762_CR28","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1177\/0272989X10393284","volume":"31","author":"EM Pullenayegum","year":"2011","unstructured":"Pullenayegum EM, et al. Calculating utility decrements associated with an adverse event: marginal Tobit and CLAD coefficients should be used with caution. Med Decis Making. 2011;31(6):790\u20139.","journal-title":"Med Decis Making"},{"issue":"6","key":"1762_CR29","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s11136-011-0018-1","volume":"21","author":"SH Kim","year":"2012","unstructured":"Kim SH, et al. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Qual Life Res. 2012;21(6):1065\u201373.","journal-title":"Qual Life Res"},{"key":"1762_CR30","volume-title":"Age-appropriateness of the EQ-5D adult and child-friendly version\u2013Testing the feasibility, reliability and validity in children and adolescents. in 23rd Scientific Plenary Meeting of the EuroQol Group in Barcelona, Spain","author":"N Wille","year":"2006","unstructured":"Wille N, Ravens-Sieberer U. Age-appropriateness of the EQ-5D adult and child-friendly version\u2013Testing the feasibility, reliability and validity in children and adolescents. in 23rd Scientific Plenary Meeting of the EuroQol Group in Barcelona, Spain. 2006."},{"issue":"2","key":"1762_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10198-009-0168-z","volume":"11","author":"JE Brazier","year":"2010","unstructured":"Brazier JE, et al. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215\u201325.","journal-title":"Eur J Health Econ"},{"key":"1762_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-4-20","volume":"4","author":"HF van Stel","year":"2006","unstructured":"van Stel HF, Buskens E. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual Life Outcomes. 2006;4:20.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"1762_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1468-2982.2007.01504.x","volume":"28","author":"C Witt","year":"2008","unstructured":"Witt C, et al. Cost-effectiveness of acupuncture treatment in patients with headache. Cephalalgia. 2008;28(4):334\u201345.","journal-title":"Cephalalgia"},{"issue":"7442","key":"1762_CR34","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/bmj.38033.896505.EB","volume":"328","author":"D Wonderling","year":"2004","unstructured":"Wonderling D, et al. Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. BMJ. 2004;328(7442):747.","journal-title":"BMJ"},{"key":"1762_CR35","unstructured":"Excellence., N.I.f.H.a.C. Position statement on use of the EQ-5D-5L value set for England (updated October 2019). 2019.\u00a0Cited 2021 22\/10\/2021."},{"issue":"5","key":"1762_CR36","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B Van Hout","year":"2012","unstructured":"Van Hout B, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in health. 2012;15(5):708\u201315.","journal-title":"Value in health"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-022-01762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-022-01762-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-022-01762-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:04:01Z","timestamp":1666767841000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-022-01762-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1762"],"URL":"https:\/\/doi.org\/10.1186\/s12874-022-01762-y","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from study participants prior to participation in the test and validation sample data collection exercises. For the validation study, ethics approval was provided by the Northwest\u2014Greater Manchester East Research Ethics Committee (REC REF: 16\/NW\/0890).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MU reports personal fees from National Institute for Health Research, grants from National Institute for Health Research, grants from Versus Arthritis, other from multiple professional conferences, grants from Stryker Ltd, grants from SERCO Ltd, other from Confederation for Advanced Research Training in Africa (CARTA) and personal fees from Clinvivo Ltd, outside the submitted work. MU reports he has been a Chief Investigator on multiple research grants from Australian National Health and Medical Research Council. FG reports grants from NIHR during the conduct of the study. MM reports grants, personal fees and honorarium for serving on advisory board from Allergan, honorarium for serving on advisory board from Novartis, personal fees and honorarium for serving on advisory board from Eli Lilly, personal fees and honorarium for serving on advisory board from TEVA, grants from Abbott, grants from Medtronic, grants from electroCore, personal fees and honorarium for serving on advisory board from Salvia. In addition, MM has a patent WO2018051103A1 issued.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}